Allergy Therapeutics PLC Appointment of a Non-Executive Director (2671X)
November 18 2014 - 2:01AM
UK Regulatory
TIDMAGY
RNS Number : 2671X
Allergy Therapeutics PLC
18 November 2014
18 November 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or the 'Company")
Appointment of a Non-Executive Director
Allergy Therapeutics (AIM: AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, is pleased
to announce that it has appointed, with immediate effect, Jean-Yves
Pavée as a Non-Executive Director; nominated by Abbott (NYSE:
ABT).
Jean-Yves Pavée is Senior Vice President, Developed Markets for
Abbott's Established Products Division. He was appointed to his
role in July 2013. Previously, he served as Divisional Vice
President, EMEA East, and Division Vice President, Pharmaceuticals,
Europe South. He joined Abbott in 1992.
Peter Jensen Chairman of Allergy Therapeutics commented:
"We are delighted towelcome Jean-Yves to the Board. He brings
extensive industry experience, which will be invaluable toour
Company as we continue to execute our global strategy."
Additional information regarding Jean-Yves Pavée:
Full name and age: Jean-Yves Frédéric Georges André Pavée-Callu,
aged 51
There are no further disclosures required under Schedule Two
paragraph (g) of the AIM rules.
For further information
Allergy Therapeutics +44 (0) 1903 845 820
Manuel Llobet, Chief Executive
Officer
Ian Postlethwaite, Finance Director
Peel Hunt LLP +44 (0) 20 7418 8900
James Steel
Clare Terlouw
FTI Consulting +44 (0) 20 3727 1000
Simon Conway
Victoria Foster Mitchell
Note to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company
focused on allergy vaccination. Ithas a growing business achieving
revenue in thelast financial yearof GBP42 million mainly in Europe
through its own sales and marketing infrastructure and further
afield through distributors. The Company is expanding its
infrastructure into theEmerging markets
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAEFXFASLFAF
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024